Cohort profile: Risk evaluation of cancers in Chinese diabetic individuals: A longitudinal (REACTION) study

Journal of Diabetes

Volumn 6, Issue 2, 2014, Pages 147-157

  Bi, Yufang ^a,b   Lu, Jieli ^a,b   Wang, Weiqing ^a,b   Mu, Yiming ^c   Zhao, Jiajun ^d   Liu, Chao ^e   Chen, Lulu ^g   Shi, Lixin ⁱ   Li, Qiang ^j   Wan, Qin ^k   Wu, Shengli ^l   Yang, Tao ^f   Yan, Li ^m   Liu, Yan ⁿ   Wang, Guixia ⁿ   Luo, Zuojie ^o   Tang, Xulei ^p   Chen, Gang ^q   Huo, Yanan ^r   Gao, Zhengnan ^s   Su, Qing ^b   Ye, Zhen ^t   Wang, Youming ^u   Qin, Guijun ^v   Deng, Huacong ^w   Yu, Xuefeng ^h   Shen, Feixia ^x   Chen, Li ^y   Zhao, Liebin ^a,b   Zhang, Jie ^a,b   Sun, Jichao ^a,b   Dai, Meng ^a,b   Xu, Min ^a,b   Xu, Yu ^a,b   Chen, Yuhong ^a,b   Lai, Shenghan ^z   Bloomgarden, Zachary T ^aa   Li, Donghui ^ab   Ning, Guang ^a,b   more..

^a BEIJING HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^f MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^g HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h Tongji Hospital   (China)

ⁱ Department of Light Industry   (China)

^j Haerbin University of Commerce   (China)

^k University of Luzhou School of Medicine   (China)

^l Xinjiang Kelamayi Peoples Hospital   (China)

^m SUN YAT SEN UNIVERSITY   (China)

ⁿ Basic Medical College   (China)

^o GUANGXI UNIVERSITY   (China)

^p Electrical Institute of Lanzhou   (China)

^q Fujian Medicine University   (China)

^r Jiangxi Peoples Hospital   (China)

^s School of Biomedical EngineeringDalian University of Technology   (China)

^t ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^u University of Anhui   (China)

^v University of Zhenzhou School of Medicine   (China)

^w CHONGQING UNIVERSITY   (China)

^x WENZHOU UNIVERSITY   (China)

^y SHANDONG UNIVERSITY   (China)

^z JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^aa MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^ab UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Cancer; Diabetes; REACTION study

Indexed keywords

CANCER; DIABETES; REACTION STUDY;

ADULT; AGED; BLOOD GLUCOSE; CHINA; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEALTH STATUS; HUMANS; LIFE STYLE; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; PREDIABETIC STATE; PREVALENCE; PUBLIC HEALTH; RISK ASSESSMENT; RISK FACTORS;

EID: 84895070193     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12108     Document Type: Article

References (28)

1. Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: Providing evidence, raising awareness and promoting action. Diabetes Res Clin Pract. 2010; 87: 2-3.
2. Yang W, Lu J, Weng J etal. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362: 1090-1101.
3. Qin XJ, Shi HZ. Major causes of death during the past 25 years in China. Chin Med J. 2007; 120: 2317-2320.
4. Giovannucci E, Harlan DM, Archer MC etal. Diabetes and cancer: A consensus report. CA Cancer J Clin. 2010; 60: 207-221.
5. Lopez AD, Mathers CD, Ezzati M etal. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet. 2006; 367: 1747-1757.
6. Lam EK, Batty GD, Huxley RR etal. Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol. 2011; 22: 730-738.
7. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009; 16: 1103-1123.
8. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer. 2009; 124: 1398-1403.
9. Parr CL, Batty GD, Lam TH etal. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: Pooled analyses of 424 519 participants. Lancet Oncol. 2010; 11: 741-752.
10. Calle EE, Rodriguez C, Walker-Thurmond K etal. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625-1638.
11. Bowker SL, Majumdar SR, Veugelers P etal. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29: 254-258.
12. Monami M, Lamanna C, Balzi D etal. Sulphonylureas and cancer: A case-control study. Acta Diabetol. 2009; 46: 279-284.
13. Libby G, Donnelly LA, Donnan PT etal. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32: 1620-1625.
14. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52: 1766-1777.
15. Landman GW, Kleefstra N, van Hateren KJ etal. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010; 33: 322-326.
16. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004; 127: 1044-1050.
17. Bodmer M, Meier C, Krähenbühl S etal. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010; 33: 1304-1308.
18. Elashoff M, Matveyenko AV, Gier B etal. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141: 150-156.
19. Ning G, Reaction Study Group. Risk Evaluation of cAncers in Chinese diabeTic Individuals: A lONgitudinal (REACTION) study. J Diabetes. 2012; 4: 172-173.
20. Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ) 2005. Available from: http://www.ipaq.ki.se/scoring.pdf (accessed 1 November 2005).
21. Moriarty DG, Zack MM, Kobau R. The Centers for Disease Control and Prevention's Healthy Days Measures - population tracking of perceived physical and mental health over time. Health Qual Life Outcomes. 2003; 1: 37.
22. World Health Organization. The WHO STEPwise approach to chronic disease risk factor surveillance (STEPS). 20 Avenue Appia, 1211 Geneva 27, Switzerland.
23. Prättälä R, Helasoja V, Laaksonen M etal. CINDI Health Monitor. Proposal for Practical Guidelines. Publications of the National Public Health Institute, Helsinki, 2001, Available from: http://www.ktl.fi/attachments/cindi_guidelines.pdf (accessed 6 June 2001).
24. Chobanian AV, Bakris GL, Black HR etal. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206-1252.
25. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005; 366: 1059-1062.
26. Zhou BF. Cooperative Meta-Analysis Group of the Working Group on obesity in China. Biomed Environ Sci. 2002; 15: 83-96.
27. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
28. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of WHO Consultation. WHO, Geneva, 1999.